Aura Biosciences Stock (NASDAQ:AURA)
Previous Close
$5.57
52W Range
$4.84 - $12.38
50D Avg
$6.91
200D Avg
$8.35
Market Cap
$271.22M
Avg Vol (3M)
$260.66K
Beta
0.43
Div Yield
-
AURA Company Profile
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
AURA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CCCC | C4 Therapeutics, Inc. |
| IMTX | Immatics N.V. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| ALXO | ALX Oncology Holdings Inc. |
| OPT | Opthea Limited |
| SEER | Seer, Inc. |
| RZLT | Rezolute, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| ORIC | ORIC Pharmaceuticals, Inc. |
| BCAB | BioAtla, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| ANTX | AN2 Therapeutics, Inc. |